Abbott Laboratories Message Board

Considering the potential impact of the "Human Brain Mapping Project", the investment to date of approximately $35,000,000 in developing the patented MANF technology, and the value attached to Amarantus Diagnostics, and the fact that the GDNF technology sold for $265,000,000 I would attach a current value to Amarantus Bioscience in the $100,000,000 range or about .45/share.

I'm looking forward to Jason Napadano's valuation.

p.s. I'm being very conservative in my approach.

.45 may be on the low side.

Considering the potential impact of the "Human Brain Mapping Project", the investment to date of approximately $35,000,000 in developing the patented MANF technology, and the value attached to Amarantus Diagnostics, and the fact that the GDNF technology sold for $265,000,000 I would attach a current value to Amarantus Bioscience in the $100,000,000 range or about .45/share.

A joint venture or "big pharma" partnership announcement and the resulting short squeeze could take it much higher but it would probably settle in the .45-.50 range.

p.s. I'm being very conservative in my approach.

One press release away from a major move higher with the recent trading volume having dropped substantially.

Amarantus Bioscience - AMBS.

The next ARNA.

The door is now wide open with any number of other viable partners: i.e. Banyan Biomarkers

On March 4, 2013, Amarantus Bioscience, Inc., a Delaware corporation (“Amarantus” or the “Company”), terminated that certain non-binding Letter of Intent (the “LOI”), dated June 30, 2012, entered into by and between the Company and Rainbow Biosciences, LLC, a wholly-owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). Pursuant to the terms of the LOI, the two companies were to investigate the feasibility of a joint venture, purchase or partnership to develop and commercialize the Company’s intellectual property. Upon further consideration of the proposed transaction, the Company elected to terminate the LOI prior to the consummation of a definitive agreement that would have defined the terms of any joint venture, purchase or partnership. Amarantus has not received funding from RBCC and the parties have never entered into any formal agreement to further the development and commercialization of the Company’s intellectual property with RBCC.

.15 by Friday is realistic as the market realizes the significance to attach to the termination of the relationship with Rainbow Coral Corporation.

It was something that I expected would happen although I thought it should have been done weeks ago.

Gerald is cleaning up the balance sheet and also eliminating situations that could delay or interfere with substantive joint ventures or partnerships.

Exciting times ahead for the AMBS shareholders. Not so much for the "shorts".

p.s. Add a few shares tomorrow. The share price isn't going to stay this low for much longer.

Note: The word is getting out to the market about the tremendous potential that the company offers to new shareholders. Realize that you already know about the opportunity before 99.9% of the future new shareholders. How much better can it get than buying shares at the bottom?